Nkarta, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2022; filed November 9, 2022. Nkarta is a clinical-stage biopharmaceutical company developing engineered, off-the-shelf natural killer cell therapies. Its lead candidates, NKX101 and NKX019, were in Phase 1 trials. The company reported no product revenue.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development | $23.4 million | $16.6 million | $64.1 million | $46.1 million |
| General and administrative | $6.8 million | $5.8 million | $19.9 million | $17.4 million |
| Total operating expenses | $30.3 million | $22.4 million | $84.0 million | $63.5 million |
| Net loss | $28.3 million | $22.4 million | $81.3 million | $63.3 million |
| Net loss per share, basic and diluted | $0.58 | $0.68 | $1.94 | $1.93 |
| Operating cash used | — | $49.7 million | $50.4 million |
At September 30, 2022, cash and cash equivalents were $39.7 million, restricted cash $2.7 million, and short-term investments $352.7 million, totaling $395.1 million. Total assets were $503.8 million, stockholders’ equity $399.3 million, and accumulated deficit $285.4 million. The filing reports no borrowings; operating lease liabilities totaled $83.5 million ($5.4 million current and $78.1 million noncurrent). Lease liabilities are not presented as debt.
Changes versus comparable periods
- Q3 operating expenses rose $7.8 million year over year, principally from higher R&D spending. Nine-month operating expenses increased $20.4 million.
- Management attributed higher R&D costs to increased clinical program activity, personnel, research supplies, and facilities. Nine-month R&D spending on NKX101 was $13.9 million and on NKX019 $7.7 million.
- Net loss increased $6.0 million in Q3 and $18.0 million for the first nine months. Higher interest income partly offset operating expense growth.
- April’s public offering of 15.3 million shares raised approximately $215.3 million net; the ATM program generated $1.6 million net in the first nine months. Weighted-average shares for the nine-month period rose to 41.9 million from 32.8 million.
- Operating cash use was broadly similar year over year. Investing cash flow shifted to $189.4 million used, mainly reflecting purchases of short-term investments and $12.1 million of property and equipment, versus $50.4 million provided in 2021.
Outlook, risks, and unusual items
- Management expects substantial future losses and increased R&D and G&A spending. It believes available cash, cash equivalents, restricted cash, and short-term investments will fund operations for at least 12 months from the filing date; this estimate depends on assumptions and may change.
- Clinical progress and enrollment face risks from trial uncertainty, COVID-related disruption, supply constraints, and reported fludarabine shortages that have delayed enrollment at some sites.
- Inflation and supply-chain delays have increased construction costs and could affect timing of the planned commercial-scale manufacturing facility. Property and equipment included $19.0 million of construction in progress.
- August lease amendments increased tenant-improvement allowances and base rent; total operating lease liabilities were $83.5 million. The filing lists $148.8 million of undiscounted future minimum lease payments before imputed interest and tenant-improvement receivable.
- Third-party patent reexaminations remain pending for two licensed patents related to NKX101. A separate reexamination of a patent unrelated to current candidates resulted in cancellation of certain claims; another reexamination remains pending.
- Other key risks include unproven CAR-NK technology, early-stage clinical results, manufacturing and sole-supplier dependence, need for additional capital, and collaboration execution. No material legal claims were reported as pending; the company stated its disclosure controls were effective at a reasonable assurance level.
Investor facts to verify
- Clinical-trial enrollment, safety, and updated efficacy data for NKX101 and NKX019; preliminary results may differ from final data.
- Whether the stated minimum 12-month funding runway remains valid as clinical, manufacturing, and facility costs evolve.
- Fludarabine availability and other supply or construction issues affecting trial timelines and manufacturing plans.
- Outcomes of the pending patent reexaminations, particularly those involving NKX101-related patents.
- Future cash burn, equity issuance and dilution, and the effect of lease and facility commitments on liquidity.